RPEL family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability by Diring, J. et al.
BIROn - Birkbeck Institutional Research Online
Diring, J. and Mouilleron, S. and Mcdonald, Neil Q. and Treisman, R. (2019)
RPEL family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability.
Nature Cell Biology 21 , pp. 845-855. ISSN 1465-7392.
Downloaded from: http://eprints.bbk.ac.uk/26778/
Usage Guidelines:
Please refer to usage guidelines at http://eprints.bbk.ac.uk/policies.html or alternatively
contact lib-eprints@bbk.ac.uk.
  
1
RPEL family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability 1 
 2 
 3 
 4 
Jessica Diring1, Stephane Mouilleron2, Neil Q. McDonald3,4 and Richard Treisman*1,5 5 
 6 
1Signalling and Transcription Group 7 
2Structural Biology Science Technology Platform 8 
3Signalling and Structural Biology Group 9 
The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK 10 
 11 
4Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck 12 
College, Malet Street, London, WC1E 7HX UK 13 
 14 
5Correspondence should be addressed to R.T. (email: richard.treisman@crick.ac.uk) 15 
 16 
SHORT TITLE: Regulation of a rhoGAP by G-actin  17 
KEYWORDS: RhoGAP, ArhGAP12, RPEL, MRTF, actin, GAP, melanoma, Rac, Cdc42 18 
  19 
  
2
ABSTRACT  20 
RPEL proteins, which contain the G-actin binding RPEL motif, coordinate cytoskeletal 21 
processes with actin dynamics. We show that the ArhGAP12- and ArhGAP32-family 22 
GTPase activating proteins are RPEL proteins. We determine the structure of the 23 
ArhGAP12/G-actin complex, and show that G-actin contacts the RPEL motif and GAP 24 
domain sequences. G-actin inhibits ArhGAP12 GAP activity, and this requires the G-actin 25 
contacts identified in the structure. In melanoma cells, ArhGAP12 suppresses basal Rac and 26 
Cdc42 activity, F-actin assembly, invadopodia formation, and experimental metastasis. In 27 
B16 melanoma cells, ArhGAP12 mutants defective for G-actin binding exhibit more effective 28 
downregulation of Rac.GTP loading following HGF stimulation, and enhanced Rac-29 
dependent processes, including invadopodia formation. Potentiation or disruption of G-30 
actin/ArhGAP12 interaction, by treatment with the actin-binding drugs latrunculin B or 31 
cytochalasin D, has corresponding effects on Rac.GTP loading. G-actin interaction with 32 
RPEL family rhoGAPs thus provides a negative feedback loop that couples Rac activity to 33 
actin dynamics. 34 
35 
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INTRODUCTION 36 
 Spatial and temporal control of the actin cytoskeleton in response to local signalling 37 
or mechanical cues plays a critical role in development and disease1-3. Underpinning it is the 38 
regulation of actin treadmilling, the dynamic transition between actin's monomeric (G-actin) 39 
and polymerised (F-actin) forms1,4, which is controlled by rho family small GTPases5,6. Rho 40 
GTPase activity is potentiated by multiple rho GEF proteins, which catalyse GTP loading 41 
and effector protein binding7,8, and antagonised by inhibitory rho GAPs, which catalyse GTP 42 
hydrolysis9,10. Both are regulated by specific subcellular targeting, and by biological and 43 
mechanical signals, but relatively little is known about how their activity responds to the 44 
status of the actin cytoskeleton.  45 
 One connection between cytoskeletal dynamics and control of protein function is 46 
provided by the RPEL proteins, which act as G-actin sensors11,12. Their regulatory domains 47 
contain RPEL motifs (Pfam PF02755), short polypeptide sequences that bind G-actin13. Two 48 
RPEL protein families, the MRTFs and the Phactrs, have been characterised11,12,14,15. The 49 
MRTFs are coactivators for the SRF transcription factor, regulating expression of dozens of 50 
cytoskeletal structural and regulatory proteins11,16,17, while the Phactrs regulate cytoskeletal 51 
dynamics by poorly understood mechanisms14,15,18,19. G-actin controls the subcellular 52 
localisation and activity of the MRTFs and Phactrs, at least in part by binding competitively 53 
with their regulatory and effector proteins, such as importin αβ and PP1, to sites within their 54 
regulatory RPEL domains14,15,20,21.  55 
 Here we identify two new RPEL protein families, the ArhGAP12 and ArhGAP32 56 
subfamilies of Rac1/Cdc42-specific GTPase activating proteins (GAPs)22-25. The ArhGAP12 57 
family is associated with actin-dependent cell surface structures and processes, including 58 
adherens junctions23,26-28, plasma membrane blebs29, phagocytosis30, and dendritic spines31, 59 
while the ArhGAP32 family proteins have been implicated in protein trafficking and neuronal 60 
development25,32. However, little is known about their regulation. We show that binding of G-61 
actin to an atypical RPEL motif adjoining the ArhGAP12 GAP domain inhibits its GAP activity 62 
  
4
for Rac1 in vitro. Disruption of the G-actin/ArhGAP12 interaction potentiates GAP activity in 63 
vivo. Our findings demonstrate that G-actin/ArhGAP12 interaction constitutes a feedback 64 
loop that couples Rac/Cdc42 GTP loading to the state of cytoskeletal dynamics.  65 
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RESULTS 66 
 67 
Two subfamilies of ArhGAP proteins contain a G-actin binding motif. 68 
 The Starlet sea anemone Nematostella vectensis A7RG60 protein contains a single 69 
canonical RPEL motif between its PH and GAP domains (http://pfam.xfam.org/family/rpel; 70 
Fig. S1a,b). The A7RG60 RPEL-GAP region is closely related to two subfamilies of ArhGAP 71 
proteins, ArhGAP9/12/15/27 and ArhGAP32/33, although the RPEL motif in these proteins 72 
lacks the conserved RPEL glutamate residue (Fig. 1a,b; Fig. S1c,d). This residue does not 73 
directly contact the bound actin, however, but contacts a second G-actin/RPEL unit in 74 
proteins containing multiple RPEL motifs33.  75 
 To test whether the ArhGAP non-consensus RPEL motif indeed binds G-actin, we 76 
performed fluorescence anisotropy assays34 (Fig. 1b, c). Peptides encompassing the 77 
A7RG60, ArhGAP12- and ArhGAP32-family RPEL motifs bound G-actin with micromolar 78 
affinities, comparable to those of the MRTFs and Phactrs13,14,34, and binding was impaired to 79 
varying extents by alanine substitution of the core RPEL arginine (Fig. 1c, Fig. S1e). 80 
Biolayer interferometry analysis of a GST-RPELArhGAP12 fusion protein gave a comparable 81 
result (2.85 μM; Fig. S1f). 82 
 83 
Intact ArhGAP12 binds G-actin 84 
In MDCK epithelial cells, where ArhGAP12 promotes cell scattering23, actin was 85 
readily detectable in ArhGAP12 immunoprecipitates, and its recovery decreased following 86 
serum stimulation, as seen with other RPEL proteins (Fig. 2a)11,14. Similarly, ArhGAP12 87 
coimmunoprecipitated with the non-polymerisable actin derivative R62D35 upon transient 88 
expression in NIH3T3 cells (Fig. 2b). ArhGAP12 did not colocalise with the F-actin 89 
cytoskeleton in either cell type (Fig. S1g). Actin binding was not affected by deletion of the 90 
SH3, WW or PH domain but was substantially reduced by the mutation or deletion of the 91 
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RPEL motif (Fig. 2b). Immobilised recombinant GST-ArhGAP12 and GST-ArhGAP32 92 
derivatives could recover purified rabbit skeletal muscle LatB-actin from solution, provided 93 
the RPEL motif was intact (Fig. 2c; Fig. S1h). Size exclusion chromatography of complexes 94 
formed between LatB-actin and ArhGAP12 ∆N resolved an apparent 1:1 complex of Mr 90 95 
kDa, whose formation was abolished by the R582A RPEL mutation (Fig. 2d); in contrast, 96 
ArhGAP1, which does not contain an RPEL motif, did not bind actin in this assay (Fig. S1i).  97 
 98 
ArhGAP12/G-actin interaction involves both the RPEL motif and sequences within the 99 
GAP domain. 100 
 Using biolayer interferometry, we determined the affinity of LatB-actin for ArhGAP12 101 
∆N∆P as 40.3 ± 1.5 nM (Fig. 3a). This is significantly greater than the ~micromolar affinity of 102 
the G-actin/RPEL motif-peptide interaction, and suggests that G-actin might contact 103 
additional sequences in the RPEL-GAP domain. To investigate interaction between G-actin 104 
and ArhGAP12 in detail, we determined the structure of ArhGAP12 ∆N∆P bound to LatB-105 
actin (hereafter ArhGAP12G-actin) at a resolution of 2.6Å (Fig. 3b; Table 1). The 106 
asymmetric unit contains four virtually identical copies of the complex, which superimpose 107 
with RMSDs ranging from 0.18 Å to 0.35 Å (over 500 Cα) (Fig. S2a). In the ArhGAP12G-108 
actin complex, ArhGAP12 forms a striking U-shape, clasping G-actin with its RPEL motif and 109 
GAP domain, which wrap around subdomains 1 and 3 (Fig. 3b). The extended 110 
ArhGAP12/G-actin interaction surface (1700 Å2) includes close contacts between the RPEL 111 
motif and the G-actin hydrophobic cleft and ledge (Fig. 3c, Fig. S2b), and between the GAP 112 
domain and a hydrophobic niche at the subdomain 1/3 interface, composed of actin I75, 113 
I175, and R177, and P109, L110, and P112 from the actin Pro-rich loop (Fig. 3d, Fig. S2c).  114 
 The ArhGAP12 RPEL motif interacts in a manner largely indistinguishable from that 115 
seen in canonical RPEL motifG-actin complexes13,33,36, but makes two additional contacts 116 
through T571 and F578 in helix α1 (Fig. 3c, Fig. S2d). Alanine substitution of the conserved 117 
RPEL motif core residue R582, or helix α1 hydrophobic residues L575 and L579, 118 
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significantly reduced recovery of LatB-actin by ArhGAP12 ∆N∆P in the pull-down assay 119 
(Fig. 3e).  120 
 The GAP domain structure is essentially identical (RMSD 0.58 Å, 164 Cα) to a 121 
previously determined structure of the ArhGAP15 GAP domain (PDB 3BYI; Fig. S2e). The 122 
aromatic sidechain of F650, from its helix α5/α7 unit, is deeply buried in the hydrophobic 123 
niche, while L642, A643 and M677 interact with the niche edges. These interactions are 124 
further stabilised by a network of hydrogen bonds formed between N641, Q646, H654, E681 125 
from the ArhGAP12 helix α5/α7 unit and actin E72, L110, I175 and K113 respectively 126 
(Figure 3d, Fig. S2c). Alanine- or charge-substitution of F650 reduced the recovery of G-127 
actin in the pulldown assay, with or without additional alanine substitutions at Q646 and 128 
H654 (Fig. 3e). Biolayer interferometry analysis demonstrated that mutation of the GAP helix 129 
α5/α7 unit reduced binding affinity ~9-fold, while the RPEL R582A mutation reduced it 1300-130 
fold; binding of actin to a protein containing both mutations was undetectable (Fig. 3f; Fig. 131 
S2f). Thus, the high binding affinity of G-actin for ArhGAP12 arises from contacts with both 132 
the RPEL motif and GAP domain. 133 
 134 
G-actin inhibits ArhGAP12 GAP activity in vitro 135 
 We next investigated the effect of ArhGAP12/G-actin interaction on GAP activity. In a 136 
colorimetric GAP assay measuring phosphate release, ArhGAP12 potentiated GTPase 137 
activity of Rac1 and Cdc42, but not RhoA (Fig. S3a-c), in agreement with previous studies of 138 
ArhGAP12/32 family members22-25, but it remains possible that other rho-family GTPases are 139 
ArhGAP12 targets. GAP activity towards Rac1 was unaffected by the presence of 140 
ArhGAP12 N-terminal sequences including the RPEL motif, or by RPEL point mutations that 141 
reduce G-actin binding (Fig. 4a), but impaired by mutation of R637, the catalytic "arginine 142 
finger" (Fig. 4a). Thus, in the absence of actin, the RPEL motif does not affect the in vitro 143 
catalytic activity of ArhGAP12.  144 
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Inclusion of increasing concentrations of LatB-actin in the GAP reactions, however, 145 
effectively inhibited ArhGAP12 GAP activity in vitro (Fig. 4b, Fig. S3d). Strikingly the RPEL 146 
mutations R582A and L575A L579A, which reduce ArhGAP12/G-actin interaction, rendered 147 
the GAP activity insensitive to inhibition by LatB-actin (Fig. 4b) as did mutations F650A and 148 
F650D, which weaken the interaction between helix 5 of the GAP domain and the actin 149 
hydrophobic niche (Fig. 4c). Thus, inhibition of ArhGAP12 GAP activity requires contact 150 
between actin and both the GAP domain and the RPEL motif.  151 
 152 
G-actin partially occludes the GTPase binding site in the complex 153 
To understand further the molecular mechanism by which G-actin binding inhibits ArhGAP12 154 
activity, we modelled the interaction of Rac and Cdc42 with ArhGAP12. Superposition of the 155 
structure of the MgcRacGAPCdc42 complex GAP domain (PDB ID 5C2J) onto that of 156 
ArhGAP12G-actin (RMSD=0.63Å for 123 Cα)  revealed a substantial steric clash – 23.7% 157 
of GTPase atoms – between G-actin and Cdc42, and superposition of the Rac1 structure 158 
(PDB 5N6O) onto this model (RMSD 0.50Å for 148 Cα), revealed a similar clash for Rac1 159 
(23.5%; Fig. 4d, Fig. S3e). To test this we co-expressed ArhGAP12 derivatives with RacG12V, 160 
which is locked in the GTP-bound state, and assessed the ability of a GST-PAK CRIB 161 
domain fusion protein to recover ArhGAP12 from cell lysates in association with Rac. RPEL 162 
and GAP domain mutations that impair G-actin/ArhGAP12 interaction increased ArhGAP12 163 
recovery in this assay (Fig. 4e). Taken together, these data suggest that GAP domain 164 
interaction with the actin hydrophobic niche constrains its position so as to inhibit interaction 165 
with its substrate GTPases. 166 
 167 
ArhGAP12 controls GTP loading on Rac and Cdc42 in melanoma cells  168 
 ArhGAP15, an ArhGAP12 family member, is implicated in maintenance of basal 169 
Rac.GTP levels in various cell types37-39. To investigate the role of ArhGAP12 in rho family 170 
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GTPase regulation we studied melanoma cells, whose behaviour in invasiveness and 171 
experimental metastasis assays is Rac/Cdc42 dependent40-44. In B16F10 melanoma cells, 172 
siRNA-mediated ArhGAP12 depletion did not appreciably affect transcription of other 173 
ArhGAP12- and ArhGAP32-family members (Fig. S4a,b), but increased GTP loading on Rac 174 
and Cdc42, (Fig. 5a,b), as did depletion of ArhGAP32 (Fig. S4c). We used the RaichuEV-175 
Rac FRET-based biosensor45 to test how ArhGAP12 affects the kinetics of GTP loading on 176 
Rac. In agreement with the pulldown experiments, the biosensor detected elevated basal 177 
GTP loading on Rac in ArhGAP12-depleted cells (Fig. 5c); following stimulation by HGF, 178 
downregulation was inhibited, taking at least twice as long to decrease to 50% of peak levels 179 
(Fig. 5d,e; Fig. S4d). Thus, ArhGAP12 antagonises Rac and Cdc42 activity in B16F10 180 
melanoma cells. 181 
 182 
ArhGAP12 controls invadopodia and experimental metastasis in melanoma cells  183 
 Invadopodia are actin-rich membrane protrusions that degrade the extracellular 184 
matrix to drive tumour cell invasion46. Depletion of ArhGAP12 potentiated invadopodia 185 
formation by B16F10 and B16F2 melanoma cells and their less invasive parent B16F0, and 186 
by MDA-MB-231 mammary carcinoma cells (Fig. 6a; Fig. S4e,f); in B16F10 cells, 187 
invadopodia formation was strongly dependent on Rac and to a lesser extent on Cdc42 (Fig. 188 
6b). ArhGAP12 depletion also significantly increased the ability of B16F10 and B16F0 cells 189 
to induce experimental metastasis in the mouse tail vein assay (Fig. 6c) without affecting cell 190 
proliferation (Fig. S4g,h). Increased metastasis was strongly dependent on Rac (Fig. 6d) and 191 
required MRTF/SRF signalling, as expected from our previous studies of B16F2 cells (Fig. 192 
6d)47. Consistent with this, ArhGAP12-depleted B16F10 cells exhibited a Rac-dependent 193 
increase in F-actin (Fig. S5a,b), which was accompanied by increased nuclear accumulation 194 
of MRTF-A and increased expression of MRTF/SRF target genes (Fig. S5c,d). ArhGAP12 195 
also contributes to the maintenance of basal Rac activity in NIH3T3 fibroblasts, where it is 196 
the only family member expressed (Fig. S5e): in resting cells, its depletion increased F-actin 197 
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levels, and promoted MRTF-A nuclear accumulation and MRTF/SRF target gene 198 
expression11 (Fig. S5f-i). ArhGAP12 therefore controls Rac-dependent processes in 199 
melanoma and fibroblast cells.  200 
 201 
G-actin binding controls ArhGAP12 GAP activity in vivo. 202 
Finally we investigated the role of G-actin in ArhGAP12 regulation in vivo. B16F10-203 
derived cell lines conditionally expressing siRNA-resistant ArhGAP12 derivatives were 204 
depleted of endogenous ArhGAP12, and their behaviour compared in the invadopodia and 205 
metastasis assays. Re-expression of both wildtype and R582A ArhGAP12 effectively 206 
suppressed the increased invadopodia formation, experimental metastasis, and F-actin 207 
formation associated with ArhGAP12 depletion; the R582A mutant was more effective than 208 
the wildtype protein at suppressing invadopodia formation, and was as effective as the 209 
wildtype protein in the other assays, even though it was expressed at lower level (Fig. 7a,b, 210 
Fig. S6a).  211 
We used the depletion-rescue approach in conjunction with the RaichuEV-Rac FRET 212 
biosensor to investigate the consequences of G-actin/ArhGAP12 interaction for Rac GTP 213 
loading in vivo. B16F10 melanoma cells transiently expressing siRNA-resistant wildtype or 214 
RPEL R582A mutant ArhGAP12 were depleted of endogenous ArhGAP12, and the kinetics 215 
of Rac GTP loading following HGF stimulation measured. In this setting, expression of 216 
ArhGAP12 R582A lowered the basal level of Rac-GTP loading more than wildtype 217 
ArhGAP12, and altered the kinetics of Rac-GTP loading such that Rac downregulation 218 
occurred more rapidly (Fig. 7c, Fig. S6b). Consistent with this, Rac.GTP pulldown assays 219 
from B16F10 cells transiently expressing ArhGAP12 derivatives, together with myc-tagged 220 
Rac, showed that Rac.GTP levels were lower in cells expressing the ArhGAP12 mutants 221 
R582A and L575A L579A, which cannot bind G-actin, than in those expressing wildtype 222 
ArhGAP12, even though the mutant proteins were less efficiently expressed (Fig. 7d). 223 
Consistent with these results, expression of ArhGAP12 R582A in tetracycline-inducible 224 
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NIH3T3 cell lines decreased F-actin levels to a greater extent than wildtype ArhGAP12 225 
(Fig. S6c,d).  226 
The preceding results show that the RPEL motif exerts an inhibitory effect on 227 
ArhGAP12 Rac GAP activity in vivo. To verify that this is a direct result of changes in 228 
ArhGAP12/G-actin interaction, we examined the effects of actin-binding drugs on ArhGAP12 229 
activity. Cytochalasin D (CD) and Latrunculin B (LatB) both bind G-actin, promoting F-actin 230 
disassembly, but have opposing effects on RPEL proteins: CD binds G-actin competitively 231 
with the RPEL motif and disrupts G-actin binding, while LatB is compatible with G-232 
actin/RPEL interaction11,12. Accordingly, treatment of B16F10 cells with CD decreased Rac-233 
GTP level, whereas LatB treatment potentiated it, as assessed using the GST-PAK pulldown 234 
assay (Fig. 7e). Strikingly, neither drug treatment affected Rac.GTP levels in ArhGAP12-235 
depleted cells, indicating that their effects require ArhGAP12 (Fig. 7f,g; Fig. S6e). Similar 236 
results were obtained upon comparison of wildtype and ArhGAP12 knockout fibroblasts (Fig. 237 
7h). Thus, G-actin controls cellular Rac GTP loading through its interaction with ArhGAP12-238 
family GAPs. 239 
  240 
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DISCUSSION 241 
 We have identified two new families of RPEL proteins, the ArhGAP12- and 242 
ArhGAP32-family rhoGAPs, which contain a single atypical RPEL motif immediately N-243 
terminal to their GAP domains. G-actin forms a 1:1 complex with ArhGAP12, inhibiting its 244 
GAP activity towards Rho and Cdc42. Actin makes canonical interactions with the RPEL 245 
motif, and also interacts with the GAP domain through a hydrophobic ‘niche’ on its 246 
subdomain 1/3 interface. Although the GAP domain contacts contribute only modestly to the 247 
overall G-actin binding affinity, they are critical for the repressive effect of actin binding on 248 
GAP activity. Inhibition of GAP activity by occlusion of the GTPase binding site is also seen 249 
in the inhibitory interaction between DLC1 and the SH3 domain of p120RasGAP48. Our 250 
results show that G-actin binding to ArhGAP12 downregulates its GAP activity in melanoma 251 
cells in vivo, sculpting the kinetics of Rac.GTP accumulation, and controlling Rac-dependent 252 
processes such as invadopodia formation and experimental metastasis.  253 
Extracellular chemical or environmental signals, and changes in cell differentiation 254 
state are all associated with changes in actin dynamics. Since G-actin diffuses rapidly, 255 
ArhGAP12/32-family members would effectively link the downstream functions of their target 256 
GTPases, which include F-actin assembly, to the general state of actin cytoskeletal 257 
dynamics, thereby constituting a feedback loop (Fig. 7i, left). ArhGAP12-family members are 258 
also enriched at specific subcellular locations, such as epithelial cell junctions and 259 
macrophage phagocytic cups23,30. In such settings they could directly monitor local G-actin 260 
fluctuations induced by their target GTPases, thereby fine-tuning GTPase activity, as part of 261 
a local homeostatic feedback loop (Fig. 7i, right). Indeed, it has been proposed that 262 
ArhGAP12 fulfils such a function at the phagocytic cup30, and we are currently investigating 263 
this further.  264 
The ArhGAP12- and ArhGAP32-family rhoGAPs contain only a single atypical RPEL 265 
motif lacking the conserved RPEL core glutamate (Pfam PF02755). Our previous studies of 266 
multivalent G-actin/RPEL complexes showed that the glutamate contacts a second RPEL/G-267 
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actin unit on its C-terminal side33,36, and it is therefore unsurprising that atypical RPEL 268 
motif peptides bind G-actin with comparable ~micromolar-range affinities13,14. We estimated 269 
the G-actin binding affinity of the intact ArhGAP12 RPEL-GAP fragment to be 40.3 ±1.5 nM, 270 
which is comparable to that estimated for the MRTF-A RPEL domain (~25nM35). We 271 
therefore think it likely that the ArhGAPs and MRTFs will be similarly responsive to changes 272 
in G-actin concentration, even though the ArhGAPs contain one rather than three RPEL 273 
motifs. The development of sensors that allow tracking of G-actin concentration and 274 
measurement of G-actin/RPEL interaction in vivo will be important to resolve this issue.  275 
The actin hydrophobic niche identified here is conserved amongst different actin 276 
family members, and it is therefore unlikely that different actins have differential effects on 277 
ArhGAP12 activity. Although not previously implicated in interactions with other G-actin 278 
binding proteins, the niche region mediates actin-actin interactions within the ADP F-actin 279 
filament49,50. In this context, however, it displays a more open conformation, with the 280 
subdomain 1 Pro-rich loop interaction being disrupted to form the phosphate exit channel. 281 
ADP-ribosylation of residue R177, at the niche edge, by bacterial toxins disrupts filament 282 
formation (reviewed in ref51). The niche makes intimate contacts with the helix 5-7 unit of the 283 
rhoGAP domain, just C-terminal to the catalytic arginine, which is implicated in GTPase 284 
recognition10. ArhGAP12 F650, which docks in the niche, is conserved or substituted by 285 
tyrosine or histidine in the other RPEL GAPs, but is generally hydrophilic in other rhoGAPs10 286 
(Fig. S7). This, and the lack of RPEL motifs in other rhoGAPs, suggests that only the 287 
ArhGAP12 and ArhGAP32 families are regulated by G-actin. 288 
ArhGAP12 is present at high levels at adherens junctions, where it promotes cell-cell 289 
adhesion23,26-28, and at other actin-regulated cell surface structures such as plasma 290 
membrane blebs, phagocytic cups and dendritic spines29-31. Both ArhGAP12 and ArhGAP15 291 
localisation is controlled by PI 3-kinase signalling30,39, and the PH domain of the ArhGAP12 292 
family member ArhGAP9 binds the phospholipid products of PI 3-kinase52. The PH domain 293 
is just N-terminal to the RPEL motif, so we are currently investigating whether G-actin 294 
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binding also affects its function. The two ArhGAP32 family GAPs, contain an SH3 domain 295 
N-terminal to the RPEL motif, and it will be interesting to see if G-actin influences its 296 
interactions. 297 
ArhGAP12 suppresses basal levels of GTP loading on Rac and Cdc42 in mouse 298 
melanoma cells, as does the ArhGAP12 family protein ArhGAP15, in diverse settings, 299 
including brain, glioma, 293 kidney cells and myeloid lineages37-39. This could occur in two 300 
ways. First, depletion of ArhGAP12 from specific subcellular locations might increase 301 
Rac.GTP at these locations, which could rapidly exchange with Rac pools elsewhere in the 302 
cell. Alternatively, depletion of ubiquitously localised ArhGAP12 might impact global 303 
Rac.GTP level directly, although one might expect such effects would be small given most 304 
cells express multiple rho GAPs9,10. Either way, depletion of ArhGAP12 in B16F10 cells 305 
raises Rac GTP loading sufficiently to potentiate invadopodia formation and experimental 306 
metastasis40-42, the latter appearing to reflect Rac-dependent F-actin assembly and MRTF 307 
activation. Interestingly, low ArhGAP12-family expression levels are associated with poor 308 
survival in human melanoma in the TCGA database (see http://www.oncolnc.org). 309 
We found that direct G-actin/ArhGAP12 interaction plays a significant role in control 310 
of ArhGAP12 GAP activity. In melanoma cells, ArhGAP12 RPEL mutants defective in actin 311 
binding exhibited greater GAP activity, were more effective at Rac downregulation following 312 
growth factor stimulation, and in at least some biological assays, such as invadopodia 313 
formation, were significantly more active than the wildtype protein. Moreover, the actin-314 
binding drugs CD and LatB had opposing effects on Rac GTP loading consistent with their 315 
differential effects on G-actin/RPEL interaction, which were ArhGAP12-dependent. 316 
Interestingly, in macrophages, which exhibit ArhGAP12-dependent phagocytosis, CD and 317 
actin siRNA inhibit Rac and Cdc42 activation, and LPS-stimulated phagocytosis30,53, while in 318 
neutrophils, LatB treatment prevents ArhGAP15-dependent Rac down-regulation following 319 
PI3K activation39. Our findings suggest that these observations reflect the direct control of 320 
ArhGAP12 family proteins by G-actin in these contexts.  321 
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 The RPEL motif present in the ArhGAP12 and ArhGAP32 proteins couples their 322 
activity to the surrounding availability of G-actin (Fig. 7i). We therefore consider it likely that 323 
these rhoGAPs will be involved in biological processes that are critically reliant on local 324 
control of F-actin assembly. Our future work will focus on elucidating how ArhGAP12 family 325 
members' activity relates to fluctuations in local G-actin concentration.  326 
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FIGURE LEGENDS 503 
 504 
Figure 1 Two families of rhoGAPs contain an RPEL motif. See also Fig. S1 and 505 
Supplementary Table 1. (a) Domain structure of ArhGAP12 and ArhGAP32 rhoGAP 506 
subfamilies. The RPEL-like motif is indicated in red. (b) Clustal X sequence alignment of the 507 
RPEL-like motifs of ArhGAP12/32 family GAPs with the RPEL motif of Nematostella 508 
vectensis A7RG60, aligned with the Pfam PF02755 HMM logo. (c) Fluorescence anisotropy 509 
analysis of LatB-actin binding to the FAM-conjugated RPEL peptides shown in (b), or 510 
derivatives in which the core RPEL arginine is replaced by alanine. Data were fitted by non-511 
linear regression; data are means ± SEM, n=6. ND, not determined.  512 
 513 
Figure 2 ArhGAP12 interaction with G-actin requires the RPEL motif. See also Fig. S1, 514 
S8 and Supplementary Table 1. (a) Endogenous ArhGAP12 was immunoprecipitated and 515 
actin recovery was analysed by immunoblot in starved MDCK cells. Cells were transfected 516 
with control or ArhGAP12 siRNA, or serum-stimulated as indicated. Data are mean ± SEM, 517 
n=4 experiments, two-tailed unpaired t-test. (b) Top, ArhGAP12 derivatives: full-length (FL), 518 
amino acids 1-791; ∆N 410-791; ∆N∆P 568-791; ∆N∆P∆R, 582-791. RPEL point mutants 519 
were R582A and L575A L579A. Bottom, nonpolymerisable actin mutant R62D was 520 
coexpressed with wildtype ArhGAP12 or RPEL mutant R582A and their interaction analysed 521 
by immunoprecipitation and immunoblotting. (c) Immobilised recombinant GST-ArhGAP12 522 
proteins were used to recover purified LatB-actin from solution; actin recovery was analysed 523 
by immunoblot. (d) Analytical gel filtration. Elution profiles of recombinant ArhGAP12 ∆N (4 524 
µM) and purified LatB-actin (5 µM) either alone (solid lines) or in a mixture (dotted lines), 525 
analysed by absorbance (top) or SDS-PAGE/Coomassie blue staining (bottom). Apparent 526 
Mr are indicated. Black and open horizontal arrowheads point to ArhGAP12 and actin 527 
respectively. Data shown in (a) and (b-d) are representative of n=4 and 3 experiments 528 
respectively.  529 
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 530 
Figure 3 Structural analysis of the ArhGAP12G-actin complex. See also Fig. S2, S8 531 
and Supplementary Table 1. (a) Octet biolayer interferometry assay. Biosensors loaded with 532 
GST-ArhGAP12 ∆N∆P were incubated with different concentrations of G-actin, which was 533 
washed out at 400s. Kd is the mean ± SEM; a representative of 3 independent experiments 534 
is shown. (b) The ArhGAP12 ∆N∆PLatB-actin complex. ArhGAP12 ∆N∆P is shown as blue 535 
ribbon, and LatB-actin in white surface representation, with subdomains indicated and the 536 
hydrophobic cleft, ledge and niche surfaces coloured in blue, pink and yellow, respectively. 537 
The GAP domain catalytic arginine finger is indicated. (c) RPEL-actin interactions. RPEL 538 
residues interacting with actin are shown as sticks; RPEL sequence, secondary structures, 539 
and interacting residues (mutated residues highlighted) are summarised below. (d) GAP 540 
domain interactions with the actin hydrophobic niche. ArhGAP12 residues interacting with 541 
the actin niche, or stabilising the orientation of the helices, are shown as sticks. GAP domain 542 
helix interaction residues and secondary structures are summarised as in (c), with asterisks 543 
indicating residues implicated in interaction with rho-family GTPases10 (catalytic arginine 544 
finger R637 in red). (e) Effect of RPEL and GAP domain mutations on G-actin binding, 545 
assessed by pulldown assay as in Fig. 2c and detected by Coomassie blue staining. LatB-546 
actin recovery, quantified relative to GST-ArhGAP12 ∆N WT, is indicated below the gels. 547 
Black and open arrowheads point to ArhGAP12 and actin respectively. Representative data 548 
of n=3 experiments. (f) Summary of Octet biolayer interferometry assays for GST-ArhGAP12 549 
∆N∆P and its mutant derivatives, and GST-RPEL. Kd is the mean ± SEM, n as indicated; 550 
n.d., no binding detectable under the assay conditions.  551 
 552 
Figure 4 G-actin inhibits ArhGAP12 GAP activity by occluding rho protein binding. 553 
See also Fig. S3, S8 and Supplementary Table 1. GAP activity towards Rac1 was assessed 554 
using a colorimetric assay for Pi release. Data were fitted by non-linear regression; data are 555 
means ± SEM, n=3 (a left, b), n=4 (a right, c). (a) Effect of ArhGAP12 truncations and point 556 
  
26
mutations of the RPEL motif or catalytic R637. (b) GAP activity is suppressed by 10 µM 557 
LatB-actin, and this requires the RPEL motif. (c) Alanine or aspartate substitutions at niche 558 
contact residue F650 do not affect GAP activity, but relieve the inhibitory effect of LatB-actin. 559 
(d) Model of Rac1 bound to ArhGAP12. The GAP domain of the MgcRacGAP:Cdc42.GDP 560 
structure (PDB ID 5C2J) was superimposed onto the GAP domain of the ArhGAP12 561 
∆N∆Pactin structure. The Rac1 structure (PDB 5N6O) was then superimposed onto the 562 
Cdc42 model (RMSD 0.50Å, 148 Cα). Exposed and occluded Rac1 residues are shown as 563 
green and red ribbons, GDP in orange. The degree of occlusion is similar for Cdc42 (23.7%) 564 
and Rac1 (23.5%). (e) Flag-ArhGAP12 derivatives and constitutively active Myc-RacG12V 565 
were co-expressed in NIH 3T3 cells; and recovery of ArhGAP12 and Myc-RacG12V in GST-566 
PAK CRIB pulldown assays assessed by immunoblotting. Representative immunoblots from 567 
3 independent experiments are shown.  568 
 569 
Figure 5 ArhGAP12 controls GTP loading on Rac and Cdc42 in melanoma cells. See 570 
also Fig. S4, S5, S8 and Supplementary Table 1. B16F10 melanoma cells were transfected 571 
with control or ArhGAP12 siRNA. (a) Rac.GTP and (b) Cdc42.GTP levels, as assessed by 572 
GST-PAK pulldown assays. Left, representative immunoblots. Right, data summary. Data 573 
are means ± SEM, n=6 (a) or n=3 (b), two-tailed unpaired t-test. (c) Increased basal Rac 574 
GTP loading in serum-starved B16F10 cells, measured using the RaichuEV-Rac FRET 575 
biosensor. FRET/CFP ratio was measured over 9 min in control (n=22) or ArhGAP12-576 
depleted (n=32) cells. Data are means ± SEM, two-tailed Mann Whitney test. (d) Kinetics of 577 
Rac GTP loading in control (n=10) and ArhGAP12-depleted (n=9) B16F10 cells following 578 
HGF stimulation, measured as in (c). Data are expressed relative to control cell value at the 579 
start of the experiment. T50, time to recover to 50% peak Rac GTP loading. Data are means 580 
± SEM. (e) Representative FRET/CFP ratio images displayed in 8-color, intensity modulated 581 
display mode. Representative images of three independent experiments. Scale bar 20 μm. 582 
 583 
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Figure 6 ArhGAP12 regulates Rac-dependent processes in cells. See also Fig. S4, 584 
S5, S8. Cells were transfected with control, ArhGAP12 or other siRNA as indicated. (a,b) 585 
Invadopodia formation by cells plated overnight on Oregon-green labelled gelatin was 586 
detected by loss of staining. (a) At least 8,507 cells, 112 images per condition from n=16 587 
wells. (b) At least 30,675 cells, 96 images per condition from n=24 wells. Data points from 588 
three experiments were combined; data are means ± SEM, two-tailed Mann Whitney test. 589 
(c,d) Experimental metastasis assay. B16F0 and F10 cells were injected in the tail vein of 590 
C57BL/6J mice. Images show lung colonisation after 12 days. Box-and-whiskers plots 591 
indicate the number of lung metastases, showing median, quartiles, and highest and lowest 592 
values. Representative results of three experiments are shown; n=5 (c) and  n=10 (d) mice 593 
per group, except B16F10/siArhGAP12 for which n=4 (c) and  n=8 (d), two-tailed Mann 594 
Whitney test.  595 
 596 
Figure 7 G-actin regulates Rac activity in melanoma cells. See also Fig. S5, S6, S8 and 597 
Supplementary Table 1. (a,b) B16F10 conditional lines expressing control or siRNA-resistant 598 
Flag-ArhGAP12 derivatives were transfected with control or ArhGAP12 siRNA. (a) 599 
Invadopodia formation assessed as in Fig. 6b. At least 22,437 cells, 96 images per condition 600 
from n=24 wells. Data points from three experiments were combined; data are means ± 601 
SEM, two-tailed Mann Whitney test. (b) Experimental metastasis assay, displayed as in Fig. 602 
6d. Representative results of three experiments are shown, n=5 mice per group, two-tailed 603 
Mann Whitney test. (c) HGF-induced Rac.GTP loading imaged using the RaichuEV-Rac 604 
biosensor. siRNA-resistant Flag-ArhGAP12 WT or R582A were transiently re-expressed in 605 
serum-starved ArhGAP12-depleted B16F10 cells. Images were acquired from control 606 
(n=96), +ArhGAP12 WT (n=58) and +ArhGAP12 R582A (n=37) cells. (i) Basal GTP loading 607 
on Rac, measured by FRET/CFP ratio over 10 min before stimulation. Data are means ± 608 
SEM, two-tailed Mann Whitney test. Note the lower expression level of ArhGAP12 R582A. 609 
(ii) Kinetics of GTP loading on Rac following HGF stimulation, normalised taking the basal 610 
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activity in control cells as 1.0. Data are means ± SEM. (d) Immunoblot analysis of GST-611 
PAK Rac pulldown assays using lysates of B16F10 cells cotransfected with Flag-ArhGAP12 612 
derivatives and Myc-Rac. Representative immunoblot from one of three independent 613 
experiments. (e) B16F10 cells, maintained in 0.3% FCS, following treatment with 614 
Cytochalasin D (CD) or Latrunculin B (LatB) for 30 min before Rac.GTP pulldown assay. 615 
Data are means ± SEM n=3, two-tailed unpaired t test. (f) Cells transfected with control or 616 
ArhGAP12 siRNA were maintained in 10% FCS and treated with CD for 30 min before 617 
Rac.GTP pulldown assays. Data are means ± SEM, n=5 (control), n=11 (siArhGAP12) two-618 
tailed unpaired t test. (g) Cells as in (f) were treated with LatB for 30 min before Rac.GTP 619 
pulldown assay. A representative immunoblot of three independent experiments is shown. 620 
(h) Wildtype and ArhGAP12 knockout MEFs were treated with LatB for 30 min, and with 621 
PDGF for 5 min before Rac.GTP pulldown assay. Data are means ± SEM, n=5 (WT), n=3 622 
(KO), two-tailed unpaired t test. (i) Global and local regulation by RPEL rhoGAP proteins.  623 
  624 
Table 1 Crystallographic data collection and structure refinement statistics. 625 
 626 
 627 
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METHODS 1 
 2 
Plasmids. ArhGAP12 cDNA (short isoform encoding a 791 amino acid-protein, Uniprot 3 
S4R248) was amplified by PCR from an NIH 3T3 cDNA library using standard techniques. 4 
ArhGAP12 derivatives were expressed in mammalian cells with N-terminal Flag tag in pEF-5 
plink11 or pcDNA4TO (Invitrogen) or as N-terminal GFP fusion in pcDNA6.2-N-EmGFP 6 
(Invitrogen), and in bacteria as GST fusion in pGex-6P-2 vector. Point mutants and siRNA- 7 
oligonucleotide 11-resistant ArhGAP12 derivatives were generated by site-directed 8 
mutagenesis (three mismatches: 5’-GAG CAT GTC-3’ to 5’-GAA CAC GTT-3’)(Quikchange, 9 
Agilent). Deletion mutants were created using the Phusion high-fidelity protocol (New 10 
England Biolabs). For lentiviral transduction, Flag-ArhGAP12 sequences were cloned into a 11 
modified pTripz vector (Dharmacon), where RFP and microRNA regulation sequences were 12 
replaced by a bGH Poly(A) sequence using In-fusion HD cloning (Takara). The ArhGAP32 13 
RPEL-GAP domain (amino-acids 339-569) was expressed in bacteria as GST fusion using a 14 
pGex-6P-2 vector. Expression plasmids for Actin R62D and Rac have been described35. All 15 
plasmids were sequenced using Sanger sequencing. 16 
 17 
Protein expression, purification and size-exclusion chromatography. Rabbit skeletal 18 
muscle LatB-actin was prepared as described34. ArhGAP12 and ArhGAP32 protein 19 
expression was induced at 37°C in Escherichia coli Rosetta (DE3) pLysS. Bacteria were 20 
harvested by centrifugation and lysed in 20 mM Tris, pH 6.8 and 8.5 respectively, 150 mM 21 
NaCl, 10 mM MgCl2, 1% Triton X-100, 1 mM DTT, 1 mM phenylmethylsulphonyl fluoride and 22 
protease inhibitors (Roche). The GST-fusion proteins were adsorbed onto a glutathione-23 
sepharose resin (GE Healthcare), and ArhGAP12 derivatives were recovered by cleavage 24 
with 3C protease overnight at 4°C in 20 mM Tris pH 6.8, 150 mM NaCl, 10 mM MgCl2, 1 mM 25 
DTT. Proteins were then purified by size exclusion chromatography using a Superdex 200 26 
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column (GE Healthcare) in 50 mM Tris, pH 6.8, 150 mM NaCl, 10 mM MgCl2, 1 mM DTT. 27 
The purity of the proteins was examined by SDS-PAGE and Coomassie brilliant blue 28 
staining (Fig. S3b). 29 
 30 
Analytical size exclusion chromatography and in vitro pulldown assays. For gel 31 
filtration analyses, 4 μM of purified ArhGAP12 derivatives or recombinant GST-ArhGAP1 32 
(Cytoskeleton, GAS01) were incubated with 5 μM or 2 µM LatB-actin respectively and 33 
loaded on a calibrated Superdex 200 (10:300) column (GE Healthcare) in 50 mM Tris, pH 34 
6.8 and 7.6 respectively, 150 mM NaCl, 10 mM MgCl2, 1 mM DTT. Fractions collected were 35 
concentrated, and a tenth of each fraction was analysed by SDS-PAGE and Coomassie 36 
brilliant blue staining. For GST pulldown experiments, glutathione-sepharose beads (GE 37 
Healthcare) were saturated with GST-ArhGAP12 or GST-ArhGAP32 from E. coli lysates, 38 
and used as an affinity resin in a binding reaction with 10 µM LatB-actin in binding buffer (50 39 
mM Tris, pH 7.0 and pH 8.5 respectively, 50 mM NaCl, 5 mM MgCl2) for 1h at 4°C. The resin 40 
was then washed 4 times in binding buffer and subjected to SDS-PAGE, Coomassie staining 41 
or Western blotting. Coomassie brilliant blue staining was performed according to standard 42 
techniques, and quantified using Image Studio after scanning with an Odyssey infrared 43 
scanner (Licor). Actin recovery was quantified relative to input GST-ArhGAP12. 44 
Unprocessed scans of blots and Coomassie gels are shown in Supplementary Figure 8. 45 
 46 
Crystallisation, data collection and refinement of the ArhGAP12•G-actin complex. The 47 
protein complex was prepared by mixing purified ArhGAP12 ∆N∆P and LatB-actin in a 1:2 48 
molar ratio and further purified by Superdex 200 size-exclusion chromatography equilibrated 49 
in 20 mM Tris, pH 8, 50 mM NaCl, 3 mM MgCl2, 0.2 mM EGTA, 0.2 mM ATP and 0.3 mM 50 
TCEP. To grow crystals, the protein solution was concentrated to 30 mg/mL. The complex 51 
was crystallised at 20°C using the sitting-drop vapour diffusion method. Drops of 0.5 μL 52 
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consisted of a 1:1 (vol:vol) mixture of protein and a well solution containing 0.1 M Bis-Tris 53 
Propane, pH 6.5, 20% PEG 3350, 0.2 M sodium thiocyanate. Crystals appeared after five 54 
days and reached their maximum size after ten days. Crystals were cryoprotected in mother 55 
liquor supplemented with 20% glycerol and then flash-frozen in liquid nitrogen. X-ray data 56 
were collected at 100 K at the ID24 beamline (mx8015) of the Diamond Light Source 57 
synchrotron (DLS, Oxford, United Kingdom). Data collection and refinement statistics are 58 
summarised in Table 1. The data set was indexed, scaled and merged using xia254. 59 
Molecular replacement was achieved by using the high resolution atomic coordinates of G-60 
actin extracted from the RPEL2•LatB-actin13 structure (PDB ID 2V52) and the GAP domain 61 
extracted from ArhGAP15 structure (PDB ID 3BYI) in PHASER55. Refinement was carried 62 
out by using Phenix56. Model building was carried out in COOT57. Model validation used 63 
PROCHECK58, and figures were prepared using the graphics program PYMOL 2.1.159. The 64 
asymmetric unit contains 4 copies of the complex. The ArhGAP12•G-actin structure has 65 
been deposited in PDB (ID 6GVC). 66 
 67 
Protein affinity measurements. Fluorescence anisotropy assays were performed as 68 
described previously34. Dissociation constants were derived by nonlinear regression analysis 69 
of the data using Prism (GraphPad software). Biolayer interferometry analysis of G-actin 70 
binding to immobilised GST-ArhGAP12 was performed using the Octet Red96 (ForteBio); 71 
typical immobilisation levels were above 2.5 nm. GST-ArhGAP12 loaded anti-GST 72 
biosensors were incubated with various concentrations of G-actin in the kinetics buffer (25 73 
mM Tris pH7.5, 100 mM NaCl, 0.1% Tween 20, 5 mM MgCl2, 0.5 mM TCEP, 1 mg/mL BSA). 74 
Binding experiments were performed in solid-black 96-well plates, at 25°C with an agitation 75 
speed of 1,000 rpm. Data analysis was done using the Octet software version 7.1 (ForteBio). 76 
Global fitting of the binding curves generated a best fit with a 1:1 model and the kinetic 77 
association and dissociation constants were calculated. The quality of the fit was assessed 78 
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by evaluation of the 2 and R2 values generated from all the fitting analyses. Experiments 79 
were repeated at least 3 times. 80 
 81 
RhoGTPase activity assays. GAP activity was measured using a colorimetric rhoGAP 82 
assay kit (Cytoskeleton, BK105). The reactions were performed in 20 µL with 4.75 µM 83 
RhoGTPase, 2 µM ArhGAP12 derivatives (Fig. S3b), in presence or absence of 10 µM LatB-84 
actin, at 37°C for the indicated time after addition of 200 µM GTP. The release of inorganic 85 
phosphate (Pi) was detected at 650 nm using a SpectraMax Plus 384-well plate reader. A 86 
KH2PO4 solution was used to calibrate the quantity of Pi (nmol) released to the absorbance. 87 
A non-linear regression analysis was applied to the data using Prism (GraphPad software). 88 
 89 
Cell lines. B16F0, B16F2, B16F10 melanoma cells, SV40 immortalised MEFs, NIH3T3 90 
fibroblasts, MDCK II epithelial cells and MDA-MB-231 breast carcinoma cells were 91 
maintained in DMEM with 10% fetal calf serum (FCS). Where indicated, cells were serum 92 
starved (0.3% FCS) overnight, then treated for 30 min with 15% FCS, 100 ng/mL HGF 93 
(Millipore, GF414), 5 µM Cytochalasin D (Merck, 250255), or 1 µM Latrunculin B (Merck, 94 
428020). NIH 3T3 monoclonal lines stably expressing Flag-tagged ArhGAP12 derivatives 95 
and the Tet repressor were generated using pcDNA4TO-Flag-ArhGAP12 and pcDNA6/TR 96 
(Invitrogen) plasmids, and selected for zeocin (200 µg/mL) and blasticidin (5 µg/mL) 97 
resistance. Expression was induced overnight with 2 µg/mL Tetracycline. B16F10 polyclonal 98 
lines conditionally expressing Flag-ArhGAP12 derivatives were generated by lentiviral 99 
transduction using pTripz-Flag-ArhGAP12 plasmids, and selected for puromycin (0.5 µg/mL) 100 
resistance. Expression was induced for 24h with 2 µg/mL Doxycycline. Cell growth was 101 
analysed following seeding and siRNA transfection of 50,000 cells in a well of a 6-well plate. 102 
Each day, cells of replicate wells were trypsinised, resuspended in media and counted using 103 
the Countess II instrument (Invitrogen). For cell cycle analysis cells were fixed after 2.5h of 104 
BrdU incorporation, counterstained with Propidium iodide, and analysed by flow cytometry 105 
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using standard methods and FlowJo software as previously described47. All cell lines tested 106 
negative for mycoplasma and were authenticated by STR profiling by Crick Cell Services. 107 
 108 
Transfection, immunoblotting and immunofluorescence. Cells were transfected with 109 
expression plasmids using Lipofectamine 2000 according to the manufacturer’s protocol 110 
(Invitrogen, 11668-019). Cells were reverse transfected with RNAi oligonucleotides using 111 
Lipofectamine RNAiMax (Invitrogen, 13778-150). siRNAs were: control 112 
UUCUCCGAACGUGUCACGU; MRTF-A/B UGGAGCUGGUGGAGAAGAA; ArhGAP32: 113 
L057176-01; Rac1: L041170-00; Cdc42: L043087-01; ArhGAP12: mouse L-040581-01 (a 114 
pool of oligonucleotides J-040581-9, -10, -11 and -12) and human L-008729-01 Dharmacon 115 
smartpools. In experiments where siRNA-resistant ArhGAP12 derivatives were re-116 
expressed, either transiently or in ArhGAP12-expressing lines, ArhGAP12 siRNA 117 
oligonucleotide 11 (GCAUUGAGCAUGUCGAAGA) was used. In MDCK II cells, the 118 
oligonucleotide targeting ArhGAP12 was GAACAGAACUGCUAAUUCAUU. Assays were 119 
performed 72h after siRNA transfection, with the exception of the experimental metastasis 120 
assay (40h); where required, siRNA-depleted cells were transfected with ArhGAP12 121 
plasmids 24h before analysis.  122 
Whole cell extract preparation and immunoblotting were performed using standard 123 
techniques. Unprocessed scans of blots are shown in Fig. S8. For phenotypic experiments, 124 
samples were taken for analysis of protein expression at the time assays were commenced. 125 
Antibodies used were against β-actin (Santa-Cruz Biotechnology, clone C4, sc47778, 126 
1:1,000 dilution), HA (Roche, 3F10, 11867431001, 1:1,000 dilution), Rac (Millipore, clone 127 
23A8, 05-389, 1:500 dilution), Cdc42 (Millipore, 05-542, 1:250 dilution), MRTF-A (Santa-128 
Cruz Biotechnology, C-19, sc21558, 1:1,000 dilution), MRTF-B (Bethyl Laboratories, A302-129 
768, 1:1,000 dilution), Myc (Crick Biological Resources Facilities, clone 9E10, 1:1,000 130 
dilution), ArhGAP12 (Sigma, HPA000412, 1:1,000 dilution), α-Tubulin (Sigma, clone B5-1-2, 131 
T5168, 1:6,000 dilution), GST (Sigma, G7781, 1:10,000 dilution) and Flag (Sigma, F7425, 132 
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1:1,000 dilution). Secondary antibodies were IRDye-680LT or -800CW conjugated (Licor, 133 
925-68022, -68023, -32212, -32214, -32219, 1:10,000 dilution). For coimmunoprecipitation 134 
experiments in MDCK cells, Alexa Fluor 790 conjugated light chain specific IgG (Jackson 135 
Immunoresearch laboratories, 211-652-171 and 115-655-174, 1:5,000 dilution) were used. 136 
Immunoblots were scanned with an Odyssey infrared scanner (Licor) and quantified using 137 
Image Studio. Immunofluorescence assays were carried out as described previously11. F-138 
actin was detected with Alexa Fluor 647- or Texas Red-Phalloidin (Invitrogen, A22287 and 139 
T7471) and DNA was counterstained using DAPI. F-actin staining was imaged in 96-well 140 
glass bottom plates on the automated Cellomics Arrayscan VTi and the intensity was 141 
measured using the Target Activation Bioapplication (Cellomics). Where indicated, cells 142 
were imaged using a confocal Laser Scanning Microscope LSM710 controlled by the Zen 143 
software (Zeiss), with a 63x/1.40 oil Plan Apochromat objective lens (Zeiss), utilising the 405 144 
(DAPI), 488 (GFP) and 561 nm (Texas-Red) lasers for excitation, and a pinhole set at 1 Airy 145 
unit. 146 
 147 
Immunoprecipitation and Rac/Cdc42 pulldown experiments. For Flag 148 
immunoprecipitation, cells were lysed in IP buffer (50 mM Tris, pH 7.8, 100 mM NaCl, 1% 149 
Triton X-100, 1 mM DTT and protease inhibitors (Roche)). The soluble fraction was 150 
precleared with Protein A-Sepharose beads (Sigma), and incubated with M2-Agarose beads 151 
(2h, 4°C, Sigma) with rotation. ArhGAP12 immunoprecipitation was performed with 152 
essentially the same protocol with the exception that it used 50 mM NaCl, Dynabeads 153 
Protein G (Invitrogen) and a pan-ArhGAP12 polyclonal antibody generated by Crick 154 
Biological Resources Facilities. Beads were washed four times in IP buffer and resuspended 155 
in SDS Laemmli buffer. Actin recovery was quantified relative to input. Rac/Cdc42 pulldown 156 
experiments were performed using 15 µL of GST-tagged human PAK1 p21-binding domain 157 
(residues 67-150, 1 µg/µL) bound to glutathione magnetic beads (Millipore, 17-10394), 158 
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carried out according to the manufacturer’s instructions. Rac/Cdc42 GTP loading was 159 
quantified relative to total Rac/Cdc42. ArhGAP12 recovery was quantified relative to input. 160 
 161 
Gene expression. Total RNA was isolated and cDNA was synthesised as described 162 
previously16. Amounts of cDNA corresponding to 10 ng of RNA were analysed in SYBR 163 
Green based real-time quantitative PCR (Invitrogen) using ABI Prism 7900HT and 164 
QuantStudio 5 detection systems (Applied Biosystems). Absolute quantification of cDNA 165 
abundance was determined using a mouse genomic DNA standard. Data were normalised 166 
to the abundance of Gapdh cDNA. Gene-specific exonic primers were as follows:  167 
Arhgap9 (CAGAGGGCACTGACCAGAAGA and TTGGCGATTAGCCGCTTTAA),  168 
Arhgap12 (ACAACCCAGGAGCGAACCT and TCGGCTTGTGCTCACATCTC),  169 
Arhgap15 (CTACAGGAGCTGTGCAAATGAGA and TTGGCTCTGCCTGTCTTGGT), 170 
Arhgap27 (GAGGCCTGGAAAGCGACTT and GGGTCGTCTCTGTAGGAATTTACG), 171 
Arhgap32 (CACCGCCTCCGAAAAATG and TGCAGACTCAGCTAACGCTAGTG),  172 
Arhgap33 (TGGCGATGATCTGGATTTCA and AAGTCAAGTCCCCGAAGTCCTT),  173 
Srf (GGTTGGAGGGAACCACTGT and CTGGGAGAAGGGGGAAGAC),  174 
Cyr61 (AATCGCAATTGGAAAAGGCA and TGAAAAGAACTCGCGGTTCG),  175 
Vcl (AGCCCAGATGCTTCAGTCAGA and GGTCAGATGTGCCAGAAAGGA),  176 
Gapdh (TCTTGTGCAGTGCCAGCCT and CAATACGGCCAAATCCGTTCA).  177 
Intronic primers were as follows:  178 
Cyr61 (CGTAAACTGCCCTGAGCCTA and GACGCGATCGAGACACTTCT),  179 
Klf7 (CACTGGCTCCCTATACCGTG and GATCCAAAGCAGGGTTTGCC),  180 
Slc2a1 (CCGGATTTACGGAACCCCTC and GCAAAGGCGGGACAAGAAAG),  181 
Srf (TCAAGGCAGCAGCAGTTTCT and CAGGCAGGGTTAGGAACCAG),  182 
Vcl (CGTCACTTGCGTTGAGTACC and GAAACCACCCACAGGTTGGA),  183 
Zyx (CAACCTGGCTCGTTCTCACT and GACCATAACGAGGGGCTCAG). 184 
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Time-lapse FRET imaging. Cells were transiently transfected with the RaichuEV-Rac 185 
FRET biosensor45, 24h before imaging. Cells were imaged in phenol-red free DMEM using 186 
an inverted microscope with Perfect Focus System (Nikon Ti2), controlled by the Micro-187 
Manager software60, with a 60x/1.4 NA Plan Apochromat objective lens (Nikon), an ASI XY 188 
stage with piezo Z, a scientific CMOS camera (Photometrics Prime), a SpectraX LED light 189 
engine (Lumencor) utilising the blue excitation light fitted with a 440/20 nm filter, an 190 
FF459/526/596-Di01 dichroic mirror (Semrock), and two emission filters (FF01-482/25 for 191 
CFP, FF01-544/24 for YFP). After background subtraction, FRET/CFP ratio images were 192 
generated using Metamorph (Molecular Devices) and represented in the intensity modulated 193 
display mode (8 colours). CFP and FRET intensities were averaged over the whole cell area 194 
using Fiji software61. For kinetics experiments, data were expressed relative to the start of 195 
the experiment, and normalised as indicated. The determination of t50 (time to downregulate 196 
to 50% of the maximum activity) for each condition is calculated using the formula: t50 = t(Min 197 
+ 50% (Max - Min)) - t(Max) where t represents time, Min the minimum value, Max the 198 
maximum value (Fig. S4d, S6b). 199 
  200 
Invadopodia assay. Invadopodia assays were carried out in 96-well glass bottom plates, 201 
coated with Poly-D-Lysine (50 µg/mL), functionalised with 0.5% glutaraldehyde, and coated 202 
for 30 min at 37°C with 33 µg/mL Oregon Green-Gelatin (Invitrogen, G13186) and 1% 203 
unlabelled gelatin in PBS. Cells (3000 per well) were seeded and incubated for 16h, fixed 204 
with 4% PFA, and stained for F-actin and DNA. Images were captured on the Cellomics 205 
Arrayscan VTi with a 5x objective and analysed using the automated Morphology Explorer 206 
Bioapplication (Cellomics). Quantitation was by loss of fluorescence, normalised to cell 207 
number. 208 
 209 
Animals and experimental metastasis assay. The experimental metastasis assays were 210 
performed as described previously47. B16F0 (900,000 cells) and B16F10 cells (200,000 or 211 
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500,000 cells) were injected into the tail vein of 7-week old C57BL/6J females, and lungs 212 
were analysed 12 days after injection by counting surface metastatic foci macroscopically. 213 
For phenotypic rescue experiments, mice were given water supplemented with 2 mg/mL 214 
Doxycycline and 1% sucrose two days prior to injection and for the duration of the 215 
experiment, and replaced every two days. ArhGAP12 knockout embryos were obtained from 216 
the Jackson Laboratories, and knockout MEFs were generated and genotyped using 217 
standard techniques.  Animal experimentation complied with all ethical regulations and was 218 
carried out under the UK Home Office Project licence P7C307997 in the Crick Biological 219 
Resources Facilities. 220 
 221 
Multiple sequence alignment and phylogenetic tree. The protein sequences of all mouse 222 
rhoGAP domains and fifty amino acids N-terminally were taken from the RefSeq database. A 223 
multiple sequence alignment was generated using default parameters in Clustal Omega, and 224 
used to produce a phylogenetic tree by the neighbour-joining method. The alignment was 225 
edited and Clustal X-coloured in Jalview (blue, hydrophobic; red, positively charged; 226 
magenta, negatively charged; green, polar; pink, cysteine; orange, glycine; yellow, proline; 227 
cyan, aromatic; white, unconserved). The cladogram was drawn using Dendroscope. 228 
 229 
Statistics and reproducibility. Each experiment was performed at least three times. 230 
Unless indicated otherwise, nonparametric two-tailed Mann-Whitney tests were used to 231 
determine statistical significance, where * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 232 
0.0001; ns, not significant. Error bars represent SEM for n independent experiments, as 233 
indicated in the legends. Statistical analyses were performed using Prism (GraphPad 234 
software).  235 
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Table 1 Crystallographic data collection and structure refinement statistics  
 
 ArhGAP12G-actin 
(6GVC) 
Data collection  
Space group P 21 
Cell dimensions  
    a, b, c (Å) 101.6, 130.2, 109.3 
    α, β, γ (°)  90, 111.1, 90 
Resolution (Å) 54.13 - 2.6 
(2.69 - 2.60)a 
Rmerge 0.17 (0.77)a 
I / σI 10.82 (1.66)a 
Completeness (%) 99.43 (95.83)a 
Redundancy 6.2 (3.4)a 
  
Refinement  
Resolution (Å) 54.13 - 2.6 
(2.69 - 2.60)a 
No. reflections 81 098 
(7 746) 
Rwork  0.208 (0.317) 
Rfree 0.252 (0.359) 
No. atoms  
    Protein 17,894 
    Ligand/ion 268 
    Water 182 
B-factors  
    Actin  48.5/47.5/53.0/52.8 
    ArhGAP12 55.3/54.6/56.0/55.0 
    Ligand/ion 53.2 
    Water 42.5 
R.m.s. deviations  
    Bond lengths (Å) 0.002 
    Bond angles (°) 0.52 
Ramachandran  
    Favored (%) 97.45 
    Allowed (%) 2.51 
    Outliers (%) 0.04 
One crystal was used for the structure 
a Values in parentheses are for highest-resolution shell 
 
 
 
